Table 5 Demographic, genetic and clinical feature in SMA cohort classified as “homogeneous” and heterogeneous “groups
From: Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen
Homogeneous group | Heterogeneous group | |
|---|---|---|
ΔHFMSE | + 2.1 | + 2.6 |
Age at onset (months) | 15.41 ± 13.4 | 16 ± 15.7 |
Age at baseline (years) | 5.3 ± 3.7 | 5.0 ± 3.2 |
SMA2 | 91% | 83% |
SMA3 | 9% | 17% |